Switzerland Courts Rheinmetall, Defense Firms for $250 Million Chip Plant
A Swiss consortium recently proposed building a facility to develop and fabricate chips in the outskirts of Zurich, according to a document viewed by Bloomberg. To finance the effort, the group plans to turn to government agencies and 'large industrial companies,' the document says.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
9 minutes ago
- Bloomberg
Pepperstone's Weston on Volatility in the Stock Market
Pepperstone Group Head of Research Chris Weston speaks to Bloomberg TV's David Ingles on volatility in stock markets following the release of weak US jobs data. Weston speaks as Asian stocks head for their longest losing streak in two years. (Source: Bloomberg)
Yahoo
30 minutes ago
- Yahoo
Darwin Nunez twist could have major impact on Alexander Isak transfer to Liverpool
Newcastle's owners could end up indirectly helping Liverpool to sign Alexander Isak. That's because Al-Hilal, the club that is interested in signing Darwin Nunez from the Reds, is majoratively owned by Saudi Arabia's Public Investment Fund — the same group that majoratively owns Newcastle. Nunez could leave Liverpool before the transfer window closes after three underwhelming seasons on Merseyside, and after Napoli dropped its interest several weeks ago due to Nunez's price tag, there are not many top-level European options remaining for the Uruguayan. The riches on offer in Saudi Arabia could appeal to Nunez, and it is reported by The Athletic that Al-Hilal has made the 26-year-old its top striking target after seeing Victor Osimhen move to Galatasaray. READ MORE: Eddie Howe throws Alexander Isak future into fresh doubt amid Liverpool transfer saga READ MORE: Liverpool transfer news LIVE: Alexander Isak bid, Rodrygo agrees terms, Tyler Morton to Lyon Other targets like Benjamin Sesko and Alexander Isak are viewed as less attainable than Nunez, which is why the Saudi Pro League club is now firmly focused on Liverpool's No.9. If Al-Hilal, funded by the PIF, signs Nunez for the Reds' reported $81 million asking price, that could be the difference between Liverpool signing Isak and Liverpool not signing Isak. Meanwhile, Isak is expected to return to Newcastle's training ground today (Monday) after ruling himself out of the pre-season tour of Asia. Isak did not travel across the world with his teammates, with the official reason being that he was carrying a slight injury, but it soon emerged what the real reason for his absence was. Isak remains keen to leave Newcastle — and he could yet get his wish, despite Liverpool seeing a $146 million bid for the player swiftly rejected last week. Despite being set to return to Newcastle's training ground, Isak has been warned by Magpies manager Eddie Howe that he won't be reintegrated before proving that he is ready to give his all for his current club. "You have to earn the right to train with us," Howe said. "We are Newcastle United. The player has a responsibility here to be part of a team and part of a squad - you have to act in the right way. So that is also at play here. "We will make sure that any player does that to earn the right to train with the group. No player can expect to act poorly and train with the group as normal."
Bloomberg
39 minutes ago
- Bloomberg
Ozempic Maker's Plight Shows Managing Markets Counts Too
Ozempic-maker Novo Nordisk A/S saw its shares take a record plunge last week, sending their peak-to-trough collapse to 70% and returning them to levels last seen in 2022. The Danish drug giant's purpose may be to improve people's lives, but investors' shrinking gains from its opening of the anti-obesity market matter too. Novo's blind spot has been failing to see its share price as an asset to manage — and exploit. For years, Novo had a relatively quiet life as one member of an insulin oligopoly alongside US peer Eli Lilly & Co. and France's Sanofi SA. While it wasn't a completely smooth ride — 2016 was dire — Novo has never seen operational and strategic challenges on the scale it's now facing. In developing Ozempic for diabetes and its sibling Wegovy for weight loss, the company suddenly found itself riding a tiger.
